Advertisement
Advertisement
U.S. Markets open in 3 hrs 54 mins
Advertisement
Advertisement
Advertisement
Advertisement

Sierra Oncology, Inc. (SRRA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
54.75+0.02 (+0.04%)
At close: 04:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close54.73
Open54.64
Bid54.69 x 1300
Ask54.76 x 800
Day's Range54.63 - 54.76
52 Week Range14.91 - 54.97
Volume199,288
Avg. Volume607,808
Market Cap824.261M
Beta (5Y Monthly)0.57
PE Ratio (TTM)N/A
EPS (TTM)-7.16
Earnings DateMar 09, 2022 - Mar 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.00
  • Business Wire

    Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting

    SAN MATEO, Calif., May 12, 2022--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company on a mission to deliver transformative therapies for rare cancers, today announced two abstracts have been accepted into the program for the 2022 Annual Meeting of the European Hematology Association (EHA). An abstract presenting the full data from the pivotal phase 3 MOMENTUM study in myelofibrosis patients who are symptomatic and anemic has been selected for oral presentation. Addition

  • Business Wire

    Sierra Oncology Reports First Quarter 2022 Results

    SAN MATEO, Calif, May 06, 2022--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first quarter ended March 31, 2022.

  • Business Wire

    Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    SAN MATEO, Calif., May 05, 2022--Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company dedicated to delivering targeted therapies for rare cancers, granted stock options to twelve new employees as approved by the Compensation Committee of the Company’s Board of Directors, under Sierra Oncology’s 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individuals enterin

Advertisement
Advertisement